Comparison of the abbott realtime high-risk human papillomavirus (HPV), roche cobas HPV, and hybrid capture 2 assays to direct sequencing and genotyping of HPV DNA

Yongjung Park, Eunhee Lee, Jonghyeon Choi, Seri Jeong, Hyonsuk Kim

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Infection with high-risk (HR) human papillomavirus (HPV) genotypes is an important risk factor for cervical cancers. We evaluated the clinical performances of two new real-time PCR assays for detecting HR HPVs compared to that of the Hybrid Capture 2 test (HC2). A total of 356 cervical swab specimens, which had been examined for cervical cytology, were assayed by Abbott Real-Time HR and Roche Cobas HPV as well as HC2. Sensitivities and specificities of these assays were determined based on the criteria that concordant results among the three assays were regarded as true-positive or -negative and that the results of genotyping and sequencing were considered true findings when the HPV assays presented discrepant results. The overall concordance rate among the results for the three assays was 82.6%, and RealTime HR and Cobas HPV assays agreed with HC2 in 86.1% and 89.9% of cases, respectively. The two real-time PCR assays agreed with each other for 89.6% of the samples, and the concordance rate between them was equal to or greater than 98.0% for detecting HPV type 16 or 18. HC2 demonstrated a sensitivity of 96.6% with a specificity of 89.1% for detecting HR HPVs, while RealTime HR presented a sensitivity of 78.3% with a specificity of 99.2%. The sensitivity and specificity of Cobas HPV for detecting HR HPVs were 91.7% and 97.0%. The new real-time PCR assays exhibited lower sensitivities for detecting HR HPVs than that of HC2. Nevertheless, the newly introduced assays have an advantage of simultaneously identifying HPV types 16 and 18 from clinical samples.

Original languageEnglish
Pages (from-to)2359-2365
Number of pages7
JournalJournal of Clinical Microbiology
Volume50
Issue number7
DOIs
Publication statusPublished - 2012 Jul 1

Fingerprint

DNA
Real-Time Polymerase Chain Reaction
Human papillomavirus 18
Human papillomavirus 16
Sensitivity and Specificity
Uterine Cervical Neoplasms
Cell Biology
Genotype
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

Cite this

@article{9b022f5eeff64436a1417596c7e9020b,
title = "Comparison of the abbott realtime high-risk human papillomavirus (HPV), roche cobas HPV, and hybrid capture 2 assays to direct sequencing and genotyping of HPV DNA",
abstract = "Infection with high-risk (HR) human papillomavirus (HPV) genotypes is an important risk factor for cervical cancers. We evaluated the clinical performances of two new real-time PCR assays for detecting HR HPVs compared to that of the Hybrid Capture 2 test (HC2). A total of 356 cervical swab specimens, which had been examined for cervical cytology, were assayed by Abbott Real-Time HR and Roche Cobas HPV as well as HC2. Sensitivities and specificities of these assays were determined based on the criteria that concordant results among the three assays were regarded as true-positive or -negative and that the results of genotyping and sequencing were considered true findings when the HPV assays presented discrepant results. The overall concordance rate among the results for the three assays was 82.6{\%}, and RealTime HR and Cobas HPV assays agreed with HC2 in 86.1{\%} and 89.9{\%} of cases, respectively. The two real-time PCR assays agreed with each other for 89.6{\%} of the samples, and the concordance rate between them was equal to or greater than 98.0{\%} for detecting HPV type 16 or 18. HC2 demonstrated a sensitivity of 96.6{\%} with a specificity of 89.1{\%} for detecting HR HPVs, while RealTime HR presented a sensitivity of 78.3{\%} with a specificity of 99.2{\%}. The sensitivity and specificity of Cobas HPV for detecting HR HPVs were 91.7{\%} and 97.0{\%}. The new real-time PCR assays exhibited lower sensitivities for detecting HR HPVs than that of HC2. Nevertheless, the newly introduced assays have an advantage of simultaneously identifying HPV types 16 and 18 from clinical samples.",
author = "Yongjung Park and Eunhee Lee and Jonghyeon Choi and Seri Jeong and Hyonsuk Kim",
year = "2012",
month = "7",
day = "1",
doi = "10.1128/JCM.00337-12",
language = "English",
volume = "50",
pages = "2359--2365",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "7",

}

Comparison of the abbott realtime high-risk human papillomavirus (HPV), roche cobas HPV, and hybrid capture 2 assays to direct sequencing and genotyping of HPV DNA. / Park, Yongjung; Lee, Eunhee; Choi, Jonghyeon; Jeong, Seri; Kim, Hyonsuk.

In: Journal of Clinical Microbiology, Vol. 50, No. 7, 01.07.2012, p. 2359-2365.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the abbott realtime high-risk human papillomavirus (HPV), roche cobas HPV, and hybrid capture 2 assays to direct sequencing and genotyping of HPV DNA

AU - Park, Yongjung

AU - Lee, Eunhee

AU - Choi, Jonghyeon

AU - Jeong, Seri

AU - Kim, Hyonsuk

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Infection with high-risk (HR) human papillomavirus (HPV) genotypes is an important risk factor for cervical cancers. We evaluated the clinical performances of two new real-time PCR assays for detecting HR HPVs compared to that of the Hybrid Capture 2 test (HC2). A total of 356 cervical swab specimens, which had been examined for cervical cytology, were assayed by Abbott Real-Time HR and Roche Cobas HPV as well as HC2. Sensitivities and specificities of these assays were determined based on the criteria that concordant results among the three assays were regarded as true-positive or -negative and that the results of genotyping and sequencing were considered true findings when the HPV assays presented discrepant results. The overall concordance rate among the results for the three assays was 82.6%, and RealTime HR and Cobas HPV assays agreed with HC2 in 86.1% and 89.9% of cases, respectively. The two real-time PCR assays agreed with each other for 89.6% of the samples, and the concordance rate between them was equal to or greater than 98.0% for detecting HPV type 16 or 18. HC2 demonstrated a sensitivity of 96.6% with a specificity of 89.1% for detecting HR HPVs, while RealTime HR presented a sensitivity of 78.3% with a specificity of 99.2%. The sensitivity and specificity of Cobas HPV for detecting HR HPVs were 91.7% and 97.0%. The new real-time PCR assays exhibited lower sensitivities for detecting HR HPVs than that of HC2. Nevertheless, the newly introduced assays have an advantage of simultaneously identifying HPV types 16 and 18 from clinical samples.

AB - Infection with high-risk (HR) human papillomavirus (HPV) genotypes is an important risk factor for cervical cancers. We evaluated the clinical performances of two new real-time PCR assays for detecting HR HPVs compared to that of the Hybrid Capture 2 test (HC2). A total of 356 cervical swab specimens, which had been examined for cervical cytology, were assayed by Abbott Real-Time HR and Roche Cobas HPV as well as HC2. Sensitivities and specificities of these assays were determined based on the criteria that concordant results among the three assays were regarded as true-positive or -negative and that the results of genotyping and sequencing were considered true findings when the HPV assays presented discrepant results. The overall concordance rate among the results for the three assays was 82.6%, and RealTime HR and Cobas HPV assays agreed with HC2 in 86.1% and 89.9% of cases, respectively. The two real-time PCR assays agreed with each other for 89.6% of the samples, and the concordance rate between them was equal to or greater than 98.0% for detecting HPV type 16 or 18. HC2 demonstrated a sensitivity of 96.6% with a specificity of 89.1% for detecting HR HPVs, while RealTime HR presented a sensitivity of 78.3% with a specificity of 99.2%. The sensitivity and specificity of Cobas HPV for detecting HR HPVs were 91.7% and 97.0%. The new real-time PCR assays exhibited lower sensitivities for detecting HR HPVs than that of HC2. Nevertheless, the newly introduced assays have an advantage of simultaneously identifying HPV types 16 and 18 from clinical samples.

UR - http://www.scopus.com/inward/record.url?scp=84862742577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862742577&partnerID=8YFLogxK

U2 - 10.1128/JCM.00337-12

DO - 10.1128/JCM.00337-12

M3 - Article

VL - 50

SP - 2359

EP - 2365

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 7

ER -